Terns Pharmaceuticals Acquired by Merck | Healthcare M&A Deal

Merck has completed the acquisition of Terns Pharmaceuticals, a pharmacy business in Delaware, for $53.00 per share. Terns Pharmaceuticals is a healthcare company focused on developing and commercializing pharmaceutical products, supporting Merck’s pharmacy acquisition strategy. Merck acquisitions in healthcare M&A aim to expand its pipeline and strengthen capabilities through this merger acquisition of Terns Pharmaceuticals. The strategic acquisition is structured as a merger acquisition via a wholly owned subsidiary, Thailand Merger Sub, and was announced with over $100M deal value; the tender offer process is governed by SEC Schedule TO filings.